on Biomind Labs Inc. (CVE:BMND.NE)
Biomind Labs Advances BMND08 with New Nano-Formulation
Biomind Labs Inc., a clinical-stage biopharmaceutical company, has announced a significant advancement for its 5-MEO-DMT candidate, BMND08. The company is now utilizing a proprietary nano-formulation platform, enhancing drug delivery precision and scalability for neuropsychiatric and neurodegenerative disorders. This follows a Phase 2 trial showcasing a 100% response rate in Alzheimer’s-related mood disorders.
The patent application for BMND08 remains in progress, having successfully navigated third-party observations that aimed to challenge its standing. This has reinforced the innovation's strategic importance within CNS therapeutics, highlighting the robustness of Biomind's intellectual property.
CEO Alejandro Antalich emphasized that entering the FDA's commercial pathway marks a transformative phase for the company. In addition, Biomind has granted 6.2 million stock options to certain directors and consultants at an exercise price of $0.35 per share.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biomind Labs Inc. news